FDA Adverse Event Malfunction Summary report: N

SYNERGY¿

MDR report key: 7587876 · Received June 11, 2018

Report

Report Number
2134265-2018-05126
Event Type
Malfunction
Date Received
June 11, 2018
Report Date
May 15, 2018
Manufacturer
BOSTON SCIENTIFIC - GALWAY
Product Code
NIQ
PMA / PMN Number
SIMILAR
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

FUJIMOTO, YOSHIHIE, ET. AL., 'DELAMINATION OF NOVEL ULTRATHIN BIOABSORBABLE ABLUMINAL POLYMER OF PLATINUM CHROMIUM EVEROLIMUS-ELUTING STENT', CARDIOASC INTERV AND THER 2018 33:97-98, HTTPS://DOI.ORG/10.1007/S12928-016-0442-9. DEVICE IS A COMBINATION PRODUCT. (B)(6). (B)(4). DEVICE EVALUATED BY MFR: THE COMPLAINT DEVICE WAS NOT RECEIVED FOR ANALYSIS. THE INVESTIGATION CONCLUSION IS OPERATIONAL CONTEXT AS THE PRODUCT MEETS THE DESIGN & MANUFACTURE SPECIFICATION BUT DUE TO ANATOMICAL/PROCEDURAL FACTORS ENCOUNTERED DURING THE PROCEDURE, PERFORMANCE WAS LIMITED. (B)(4).

Description of Event or Problem · 1

IT WAS REPORTED VIA LITERATURE THAT POLYMER DELAMINATION OCCURRED. THE 90% STENOSED TARGET LESION WAS LOCATED IN THE SEVERELY CALCIFIED MID-LEFT ANTERIOR DESCENDING CORONARY ARTERY (LAD). AFTER PREDILATATION, DELIVERY OF A 24MM SYNERGY STENT IN THE MID-LAD WAS ATTEMPTED. HOWEVER, IT WOULD NOT ADVANCE TO THE TARGET LESION IN THE MID-LAD EVEN WITH THE A NON-BSC GUIDE EXTENSION CATHETER. ROTATIONAL ATHERECTOMY WAS PERFORMED. A DURABLE POLYMER EVEROLIMUS-ELUTING STENT WAS THEN DEPLOYED. THE FINAL ANGIOGRAM SHOWED A GOOD RESULT. SCANNING ELECTRON MICROSCOPY DEMONSTRATED DAMAGE TO THE BIOABSORBABLE POLYMER OF THE SYNERGY STENT; MOST OF THE DAMAGE WAS DELAMINATION OF ABLUMINAL POLYMER. IT WAS CONCLUDED THAT DELAMINATION OF ABLUMINAL BIOABSORBABLE POLYMER MAY OCCUR MORE EASILY AND SEVERELY WHEN IT IS DELIVERED THROUGH A CALCIFIED CORONARY ARTERY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
430024 SYNERGY¿ CORONARY DRUG-ELUTING STENT NIQ BOSTON SCIENTIFIC - GALWAY UNK776

Patients

Seq Age Sex Outcome Treatment
1 76 YR